Please find below the list of PhD projects funded from 2020 on, in Tours and Montpellier, in the antibody field. This list is susceptible to changes as co-fundings are obtained by the teams. For more information on the project or the recruitment procedure, please refer to the link provided for each subject.
Tours
Unravelling the oxytocine-vasopressin system to improve social interaction deficits in mouse models of autism.
Scientific Responsible name : Dr. Lucie Pellissier (UMR PRC)
Funder(s) : ERC – MAbImprove
Selective modulation of FSH receptor-induced signaling pathways in vivo, consequences on ovarian and testicular functions.
Scientific Responsible name : Dr. Eric Reiter (UMR PRC)
Funder(s) : INRA – MAbImprove
Inhaled anticancer Ab – improving their efficacy by boosting mucosal immune responses?
Scientific Responsible name(s) : Dr. Nathalie Heuzé-Vourc’h (U1100 CEPR)
Funder(s) : Région CVL – MAbImprove
Study of the relationships between body composition and pharmacokinetics of therapeutic monoclonal antibodies in the treatment of metastatic colorectal cancer.
Scientific Responsible name(s) : Pr. Thierry Lecomte – Dr David Ternant (EA 7501 GICC)
Funder(s) :Région CVL – MAbImprove
Analyse multi-échelle de production de biomédicaments par spectroscopie Raman
Scientific Responsible name : Pr. Igor Chourpa (EA6295 NMNS)
Funder(s) : Fondation Philippe Maupas – MAbImprove
Thromboses associées aux thrombopénies induites par l’héparine: Nouveau mécanisme physiopathologique et perspective thérapeutique innovante.
Scientific Responsible name : Dr. Jérôme Rollin (EA 7501 GICC)
Funder(s) : Région CVL – MAbImprove
Development of original armed antibodies for the breast cancer treatment”
Scientific Responsible name(s) : Dr. Nicolas Joubert – Dr. Caroline Denevault (EA 7501 GICC)
Funder(s) : Projet région CVL – MAbImprove
Montpellier
Functional validation of a new type of therapeutic bi-specific antibody for applications in digestive cancers.
Selection done through CBS2 Doctoral School procedure
Scientific Responsible name : Pr. Marie-Alix Poul (IRCM)
Funder(s) : Université de Montpellier – MAbImprove
Improving Natural Killer (NK)-based immunotherapy: Combination of monoclonal antibodies and chimeric antigen receptors (CAR NK).
Selection done through CBS2 Doctoral School procedure
Scientific Responsible name : Dr Martin Villalba (IRMB)
Funder(s) : Université de Montpellier – MAbImprove